• Pathologically confirmed or clinically diagnosed HCC

• Diagnosis of HCC with TACE refractoriness according to the criteria proposed by Japan Society of Hepatology (2021)

• Patients who have Tumor recurrence after surgical resection or ablation are allowed to be included

• At least one measurable intrahepatic target lesion

• Child-Pugh class A/B

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Tumor extent \<70% liver occupation

• Candidates for SIRT must be confirmed suitable for SIRT after evaluation (including SPECT/CT evaluation after arterial perfusion with 99Tc-MAA)

• Adequate organ and hematologic function with platelet count ≥50×10\^9/L, leukocyte \>3.0×10\^9/L, Neutrophil count ≥1.5×10\^9/L, haemoglobin ≥85 g/L, ALT and AST≤5×ULN, albumin ≥28 g/L, total bilirubin ≤3× ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds

• Life expectancy of at least 3 months